Tumor Biology

, Volume 35, Issue 3, pp 2035–2045 | Cite as

Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer

  • Yuanting Xiao
  • Sheng Zhang
  • Guofang Hou
  • Xiaobei Zhang
  • Xiaomeng Hao
  • Jin Zhang
Research Article


This study selected luminal-type breast cancer patients as the study subjects. The patients were divided into groups according to the presence of diabetes and the types of medication used, and the patients' clinicopathological characteristics and prognostic indicators were explored. A total of 5,785 patients with luminal-type breast cancer admitted to Tianjin Medical University Cancer Institute and Hospital between January 2002 and December 2006 were selected as the study subjects. The subjects included 680 breast cancer patients with diabetes and 5,105 breast cancer patients without diabetes. The patients were divided into Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes. Each subtype was further divided into a metformin group, a non-metformin group, and a nondiabetic group. The research indicators included breast cancer mortality, age, body mass index (BMI), amenorrhea, the presence of cardiovascular and cerebrovascular disease, pathological stage, pathological type, lymph node involvement, vessel carcinoma embolus, and the chemotherapy and endocrine regimen. A Kaplan–Meier analysis was conducted to analyze the differences in breast cancer mortality rates among the groups. The Cox proportional hazard model was adopted to detect independent factors related to prognosis. Kaplan–Meier univariate analysis showed that for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes, the cancer-specific mortality rates differed significantly among the metformin, non-metformin, and nondiabetic groups. The 5-year survival rates were 94 %, 82 %, and 91 % (P = 0.002); 93.5 %, 81 %, and 89 % (P < 0.001); and 84 %, 77 %, and 83 % (P = 0.035) for the subtypes within each group, respectively. Cox regression multivariate analysis showed that compared with the metformin group, all three subtypes of the, the non-metformin group showed poorer prognosis (hazard ratio [HR], 3.579; 95 % confidence interval [CI], 1.506–8.506 [P = 0.004]; HR, 3.232; 95 % CI, 1.839–5.678 [P < 0.001]; HR, 2.034; 95 % CI,1.019–4.059 [P = 0.044] for Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+, respectively). Compared with the metformin group, the diabetic group showed poorer prognosis only for the Luminal B (high ki67) subtype (HR, 1.762; 95 % CI, 1.033–3.005 [P = 0.038]). In addition, for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subgroups, there was a higher proportion of elderly patients (P < 0.001) and postmenopausal patients (P < 0.001) in the metformin and non-metformin groups than in the nondiabetic group. Moreover, the probability of having cardiovascular and cerebrovascular disease was also higher (P < 0.001) in the metformin and non-metformin groups. For the Luminal B (high ki67) and Luminal B (her-2/neu +) subgroups, there was a higher proportion of obese patients in the metformin and non-metformin groups (P < 0.001). In terms of clinical characteristics, for the Luminal B (high ki67) subtype, the proportion of patients with invasive ductal carcinoma was lower in the non-metformin group than in the other two groups (P = 0.001). In both the metformin and non-metformin groups, the proportion of T3/4 patients was higher (P < 0.001), the proportion of patients with lymph node metastasis was higher (P = 0.001), and the proportion of patients with vessel carcinoma embolus was higher (P = 0.001) compared with the nondiabetic group. In conclusion, compared with the metformin group, the non-metformin group had a poorer prognosis for all subtypes of luminal breast cancer. In the diabetic group, only patients with the Luminal B (high ki67) subtype exhibited a poorer prognosis. Therefore, different diabetes medication may have a different impact on the prognosis of different subtypes of luminal breast cancer.


Breast cancer Luminal B ki67 Diabetes 



We thank Dr. P. Janaina for helping us edit the langue of this manuscript.

Conflicts of interest



  1. 1.
    Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4(6):650–4.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5 Suppl 1:S2–8.PubMedCentralPubMedGoogle Scholar
  5. 5.
    He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23(7):1771–80.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Bayraktar S, Hernadez-Aya LF, Gonzalez-Angulo AM, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118(5):1202–11.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Jiralerspong S, Palla SL, Gonzalez-Angulo AM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res. 2012;24(4):388–98.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012;23(11):1785–95.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen WW, Shao YY, Shau WY, Lin ZZ, Lu YS, Chen HM, et al. The impact of diabetes mellitus on prognosis of early breast cancer in Asia. Oncologist. 2012;17(4):485–91.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol. 2012;29(3):1576–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29(1):40–6.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159–69.PubMedGoogle Scholar
  14. 14.
    Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res. 1972;32(2):233–8.PubMedGoogle Scholar
  15. 15.
    Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A. 1976;73(12):4536–40.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    White MF. Insulin signaling in health and disease. Science. 2003;302(5651):1710–1.PubMedCrossRefGoogle Scholar
  17. 17.
    Jones RA, Moorehead RA. The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2008;13(4):407–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1(4):339–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2008;1(5):369–75.CrossRefGoogle Scholar
  21. 21.
    Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013;110(3):972–7.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Samarajeewa NU, Ham S, Yang F, Simpson ER, Brown KA. Promoter-specific effects of metformin on aromatase transcript expression. Steroids. 2011;76(8):768–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Bershteĭn LM, Turkevich EA, Boiarkina MP. Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes. Vopr Onkol. 2012;58(2):194–8.PubMedGoogle Scholar
  25. 25.
    Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011;12(12):1063–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;100(3):389–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci. 2012;1271:37–43.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15(10):1083–101.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr. 2012;32:311–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMedCrossRefGoogle Scholar
  33. 33.
    Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti IA. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7(12):51446.CrossRefGoogle Scholar
  34. 34.
    Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yuanting Xiao
    • 1
  • Sheng Zhang
    • 2
    • 3
    • 4
  • Guofang Hou
    • 2
    • 3
    • 4
  • Xiaobei Zhang
    • 2
    • 3
    • 4
  • Xiaomeng Hao
    • 2
    • 3
    • 4
  • Jin Zhang
    • 2
    • 3
    • 4
  1. 1.Surgical DepartmentTianhe HospitalTianjinChina
  2. 2.3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research CenterTianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of CancerTianjinChina
  3. 3.Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of EducationTianjinChina
  4. 4.Key Laboratory of Cancer Prevention and TherapyTianjinChina

Personalised recommendations